ArticleVaccine2004
A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague.
Article in Vaccine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 87 citations in OpenAlex.
- The first key for the Priority Pathogens: Protective immunogens in development of vaccines and medications.Biosafety and health · 2026Review
- Live Plague Vaccine Development: Past, Present, and Future.Vaccines · 2025Review
- Article
- Development of a dual antigen lateral flow immunoassay for detecting Yersinia pestis.PLoS neglected tropical diseases · 2022Article
- DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses.Emerging microbes & infections · 2021Article
- Plague vaccines: new developments in an ongoing search.Applied microbiology and biotechnology · 2021Review
- Review
- An optimized secretory expression system and immunogenicity evaluation for glycosylated gp90 of avian reticuloendotheliosis virus.Veterinary research · 2020Article
- New Promising Targets for Synthetic Omptin-Based Peptide Vaccine against Gram-Negative Pathogens.Vaccines · 2019Article
- Humoral and cellular immune responses to Yersinia pestis Pla antigen in humans immunized with live plague vaccine.PLoS neglected tropical diseases · 2018Article
- Plague Vaccine Development: Current Research and Future Trends.Frontiers in immunology · 2016Review
- Plague Vaccines: Status and Future.Advances in experimental medicine and biology · 2016Review
- Intranasal co-delivery of IL-6 gene enhances the immunogenicity of anti-caries DNA vaccine.Acta pharmacologica Sinica · 2014Article
- Evaluation of YadC protein delivered by live attenuated Salmonella as a vaccine against plague.Pathogens and disease · 2014Article
- Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaques.Human vaccines & immunotherapeutics · 2014Article
- Article
- DNA immunization.Current protocols in microbiology · 2013Article
- Co-delivery of ccl19 gene enhances anti-caries DNA vaccine pCIA-P immunogenicity in mice by increasing dendritic cell migration to secondary lymphoid tissues.Acta pharmacologica Sinica · 2013Article
- Plague vaccines: current developments and future perspectives.Emerging microbes & infections · 2012Review
- Chimeric flagellin expressed by Salmonella typhimurium induces an ESAT-6-specific Th1-type immune response and CTL effects following intranasal immunization.Cellular & molecular immunology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
There is an urgent need to develop effective vaccines against pneumonic plague, a highly lethal and contagious disease caused by the Gram-negative bacterium Yersinia pestis. Here we demonstrate that a novel DNA vaccine expressing a modified V antigen (LcrV) of Y. pestis, with a human tissue plasminogen activator (tPA) signal sequence, elicited strong V-specific antibody responses in BALB/c mice. This tPA-V DNA vaccine protected mice from intranasal challenge with lethal doses of Y. pestis. In comparison, a DNA vaccine expressing the wild type V antigen was much less effective. Only tPA-V formed oligomers spontaneously, and elicited a higher IgG2a anti-V antibody response in immunized mice, suggesting increased TH1 type cellular immune response. Our data indicate that antigen engineering is effective in inducing high quality protective immune responses against conformationally sensitive antigens. These results support that optimized DNA vaccines have the potential to protect against bacterial pathogens than is generally recognized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.